5 3/4 Use of 5-membered fused aromatic heterocyclic compounds as HCV NS3/NS4 protease inhibitor

• Main Authors: CHOI, HO IL, KIM, SEON YEONG, KIM, SEONG GYU, AHN, SANG YEOL, JANG, SEUNG GU, BANG, JEONG GYU
• Format: Patent
• Language: English; Korean
• Published: 23.07.2001
• Edition: 7
• Subjects: HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES

PURPOSE: A 5-membered fused aromatic heterocyclic compound, its intermediate body, derivatives and Yohimbine compounds are provided, which can be used as HCV NS3/NS4 protease inhibitor, so that it is useful as an alternative compound of existing HCV medicine. CONSTITUTION: A process for the preparation of 5-membered fused aromatic heterocyclic compound(formula) comprises the steps of: adding Tryptophyl bromide and 3-acetylpyridine in methanol, and mixing evenly; leaving the mixed compound for 2days at room temperature to be precipitated, and filtering the precipitate; concentrating the filtrate under decompression, and storing for 24hrs; filtering the precipitate to get 3-acetyl-1-£beta-(beta-indolyl)ethyl|pyridinium bromide salt. Other examples of the 5-membered fused aromatic heterocyclic compounds are Indoloquinolizidine, Indoloquinolizidine diester, Indoloquinolizidine Aldehydoester, Hirsutine, £beta-(beta-pyridyl)acrylic acid|, Methyl beta-(beta-pyridyl)acrylate, 3-(beta-Varbomethoxyvinyl)-1-£beta-(beta-indonyl)ethyl|pyridium Bromide, 1,2,6,7-Tetrahydroindolo£2,3-a|quinolizines, Pseudoyohimbine. 본 발명은 HCV NS3/NS4 프로테아제를 억제하는 화합물과 합성과정에서 생성되는 합성 중간체에 관한 것으로서 좀더 자세히는 5-원환 융합 방향족 헤테로사이클릭 화합물(5-membered fused aromatic heterocyclic compound), 그 중간체, 유도체 및 요힘빈 계통 화합물의 HCV NS3/NS4프로테아제 억제제 용도에 관한 것이다.